Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 20/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2428602 | 0.93 | PTGER4 (0.87) | PTGER4 | |
| SCHEMBL2434183 | 0.93 | PTGER4 (0.87) | PTGER4 | |
| SCHEMBL3230599 | 0.93 | PTGER4 (0.87) | PTGER4 | |
| SCHEMBL3231135 | 0.93 | PTGER4 (0.87) | PTGER4 | |
| SCHEMBL2926374 | 0.93 | PTGER4 (0.86) | PTGER4 | |
| SCHEMBL1590717 | 0.92 | PTGER4 (0.85) | PTGER4 | |
| SCHEMBL1590114 | 0.92 | PTGER4 (0.85) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL3569590 | 0.90 | PTGER4 (0.82) | PTGER4CYP1A2CYP2D6 | |
| SCHEMBL3570750 | 0.89 | PTGER4 (1.00) | PTGER4 | |
| SCHEMBL3563657 | 0.89 | PTGER4 (1.00) | PTGER4CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1886993-B1 | BENZO[F]ISOINDOLE DERIVATIVES WITH AFFINITY TO THE EP4 RECEPTOR | GLAXO GROUP LTD (GB) | 2013-09-18 | — | — | EP | disclosed |
| US-7732622-B2 | Naphthalene derivatives | GLAXO GROUP LIMITED (GB) | 2010-06-08 | — | — | US | disclosed |
| US-20080234358-A1 | E-series of prostaglandin (EP) receptors; [[4-(4,9-dipropoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl) phenyl]acetic acid | CONGREVE MILES STUART | 2008-09-25 | — | — | US | disclosed |
| EP-1886993-A1 | BENZO[F]ISOINDOLE DERIVATIVES WITH AFFINITY TO THE EP4 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-02-13 | — | — | EP | disclosed |
| US-20070088068-A1 | Benzo[F]Isoindole Derivatives With Affinity To The EP4 Receptor | CONGREVE MILES S | 2007-04-19 | — | — | US | disclosed |
| US-7166631-B2 | Benzo[f]isoindole derivatives with affinity to the EP4 receptor | GLAXO GROUP LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| US-20050080257-A1 | Benzo'fisoindole derivatives with affinity to the ep4 receptor | GLAXO GROUP LIMITED (GB) | 2005-04-14 | — | — | US | disclosed |
| EP-1368312-A1 | BENZO'F!ISOINDOLE DERIVATIVES WITH AFFINITY TO THE EP4 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002064564-A1 | BENZO'F!ISOINDOLE DERIVATIVES WITH AFFINITY TO THE EP4 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080257-A1 | Benzo'fisoindole derivatives with affinity to the ep4 receptor | PTGER4, PTGER1, PTGER3 | PTGER4 1/4885CYP1A2 532/4885CYP2D6 467/4885 |
| US-20070088068-A1 | Benzo[F]Isoindole Derivatives With Affinity To The EP4 Receptor | PTGER4, PTGER1, GPR4 | PTGER4 1/4885CYP1A2 376/4885CYP2D6 346/4885 |
| US-20080234358-A1 | E-series of prostaglandin (EP) receptors; [[4-(4,9-dipropoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl) phenyl]acetic acid | PTGER3, OPRL1, PTGER1 | PTGER4 21/4885CYP1A2 567/4885CYP2D6 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.